# NewcelX Ltd. (NCEL)

> Source: Nexqual · https://nexqual.com/NCEL · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, NewcelX Ltd. (NCEL), nexqual.com/NCEL" · informational, not investment advice.

**Price:** USD 2.85 (+9.20% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 2.61 · day 2.61–2.9 · 52w 1.83–17.25 · market cap $16.5M · NCM

## Key facts
- Total return with dividends: 1Y -82.5% vs S&P 500 +18.1%; 5Y -99.7% vs S&P 500 +85.1%.

## Analysts
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-13 | Laidlaw & Co. | Initiated | Buy | $23 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -82.5% | -99.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -82.6% | -68.7% |
| Volatility (annualized) | 112.8% | 112.5% |
| Max drawdown | -88.9% (Oct 2025→Mar 2026) | -99.8% (Oct 2021→Dec 2025) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/NCEL · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt